CLAIMS:

1. A use of a compound of Formula I or a salt thereof



(I)

in preparation of a pharmaceutical composition for prevention or treatment of an ectoparasite infestation in a non-human mammal.

2. A use of a compound of Formula II or a salt thereof



(II)

in preparation of a pharmaceutical composition for prevention or treatment of an ectoparasite infestation in a non-human mammal.

3. A use of 5-chloro-*N*-[2-[4-(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine or a salt thereof in preparation of a pharmaceutical composition for prevention or treatment of an ectoparasite infestation in a non-human mammal.

4. A use of a compound of Formula IV or a salt thereof



(IV)

in preparation of a pharmaceutical composition for prevention or treatment of an ectoparasite infestation in a non-human mammal.

5. The use according to any one of claims 1 to 4, wherein the pharmaceutical composition is to be administered topically.

6. The use according to any one of claims 1 to 4, wherein the pharmaceutical composition is to be administered parenterally.

7. The use according to any one of claims 1 to 6, wherein the non-human mammal is infested with the ectoparasite.

8. The use according to any one of claims 1 to 6, wherein the non-human mammal is at risk of infestation with the ectoparasite.

9. The use according to any one of claims 1 to 8, wherein the ectoparasite is an arthropod.

10. The use according to any one of claims 1 to 8, wherein the ectoparasite is from the family *Ixodidae*, *Argasidae*, *Psoroptidae*, *Sarcoptidae*, *Muscidae*, *Trichodectidae* or *Pulicidae*.

11. The use according to any one of claims 1 to 8, wherein the ectoparasite is selected from the group consisting of *Boophilus spp, Rhipicephalus spp, Dermacentor spp, Hyalomma*

spp, Amblyomma spp, Otobius spp, Ornithodoros spp, Damalinia spp, Stomoxys spp, Bovicola spp and *Ctenocephalides spp.*

12. The use according to any one of claims 1 to 8, wherein the ectoparasite is a flea, tick or fly.

13. The use according to any one of claims 1 to 8, wherein the ectoparasite is a flea.

14. The use according to any one of claims 1 to 8, wherein the ectoparasite is a tick.

15. The use according to any one of claims 1 to 14, wherein the composition is a solid.

16. The use according to any one of claims 1 to 14, wherein the composition is a liquid or gel.

17. The use according to claim 16, wherein the liquid or gel is for spraying, dipping, or spotting onto the non-human mammal.

18. The use according to claim 16 or 17, wherein the compound is present in the liquid composition at 0.01 to 50.0% by weight.

19. The use according to claim 16 or 17, wherein the compound is present in the liquid composition at 0.02 to 10.0% by weight.

20. The use according to any one of claims 1 to 19, wherein a solid article comprises the composition.

21. The use according to claim 20, wherein the solid article is a collar, a collar tag, an ear tag, a tail tag, a limb band or a halter.

22. The use according to claim 20 or 21, wherein the solid article comprises a polymeric material.

23. The use according to any one of claims 1 to 22, wherein the non-human mammal is cattle, sheep, goats, pigs, dogs, cats or horses.

24. A pharmaceutical composition comprising a compound of Formula I or a salt thereof



(I)

and a pharmaceutically acceptable carrier or diluent in a unit dosage form.

25. A pharmaceutical composition comprising a compound of Formula II or a salt thereof



(II)

and a pharmaceutically acceptable carrier or diluent in a unit dosage form.

26. A pharmaceutical composition comprising 5-chloro-*N*-[2-[4-(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine or a salt thereof
and a pharmaceutically acceptable carrier or diluent in a unit dosage form.

27. A pharmaceutical composition comprising a compound of Formula IV or a salt thereof



(IV)

and a pharmaceutically acceptable carrier or diluent in a unit dosage form.

28. A composition comprising the compound of Formula I or a salt thereof and a pharmaceutically acceptable carrier or diluent, wherein the composition is suitable for topical administration to a non-human mammal



(I).

29. A composition comprising a compound of Formula II or a salt thereof and a pharmaceutically acceptable carrier or diluent, wherein the composition is suitable for topical administration to a non-human mammal



(II).

30. A composition comprising 5-chloro-*N*-[2-[4-(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine and a pharmaceutically acceptable carrier or diluent, wherein the composition is suitable for topical administration to a non-human mammal.

31. A composition comprising a compound of Formula IV or a salt thereof and a pharmaceutically acceptable carrier or diluent, wherein the composition is suitable for topical administration to a non-human mammal



(IV).

32. The composition according to any one of claims 28 to 31, wherein the composition is a powder.